Bernie Bochner, MD

1.1K posts

Bernie Bochner, MD banner
Bernie Bochner, MD

Bernie Bochner, MD

@bbmdmsk

Attending Surgeon, Sir Murray Brennan Endowed Chair in Surgery, Memorial Sloan Kettering Cancer Center. #bladder #prostate #kidney #cancer Opinions are my own

Manhattan, NY Katılım Aralık 2010
1.7K Takip Edilen3K Takipçiler
Bernie Bochner, MD
Bernie Bochner, MD@bbmdmsk·
TURBT is one of the most impt surgical skills in managing #bladdercancer 2026 course was another big success. Thank you @olympusamerica for your support Incredible group of residents fellows and attendings there this year. Thx @JoshMeeks and John Sfakianos for helping teach
Bernie Bochner, MD tweet media
English
0
12
58
5.3K
Bernie Bochner, MD
Bernie Bochner, MD@bbmdmsk·
This study does not rule out the importance of the PLND for bladder cancer patients Devil is always in the details
English
1
3
14
1.5K
Bernie Bochner, MD
Bernie Bochner, MD@bbmdmsk·
COMPLICATIONS: S1011 reported the highest gr3-5 comp rate of any published cystectomy series, 2x higher than most contemp surgical RCTs (44% in the control arm!). A German multicent trial found appr 1/2 the Gr3-5 complic rate and NO diff in morb or mortality with ePLND v sPLND
English
1
1
8
1.5K
Bernie Bochner, MD
Bernie Bochner, MD@bbmdmsk·
Not true. RC and a thorough PLND cures about 1/3 of node + bladderCA pts with surgery ALONE. S1011 enrolled relatively low risk pts (their control performed 10% better than designed) and expected an unrealistically large benefit from the ePLND (10% ⬆️3 yr RFS)=poor design.
Drew Moghanaki@DrewMoghanaki

Can we please put to rest the idea that treating lymph nodes helps patients with cancer live longer? Once again, we see no meaningful benefit and only harms—this time in a phase III RCT for bladder cancer. @QuadShotNews nejm.org/doi/10.1056/NE…

English
2
10
41
8K
Bernie Bochner, MD
Bernie Bochner, MD@bbmdmsk·
@MaxKates Very impt point @MaxKates The benefit of IO + BCG upfront is a very limited improvement in preventing non-progressive, non-lethal HG tumors. The toxicity and financial costs are high. My opinion is start with BCG and reassess the need for combo rx in the non responders
English
1
3
27
934
Max Kates
Max Kates@MaxKates·
Fellow Uros, w/CREST the relative difference here-32% does not tell the story. In fact 2 year absolute EFS difference is 5%. A 1-2% point swing would be a negative trial like Alban. CIS findings are exploratory based on a few patients & underpowered.
UroToday.com@urotoday

#CREST Trial: Sasanlimab immunotherapy + BCG in BCG-naive #BladderCancer. Sam Chang, MD, MBA @VUMCurology joins @zklaassen_md @GACancerCenter to discuss this three-arm study of over 1,000 patients showing a remarkable 32% reduction in event-free survival events with the combination therapy. The trial demonstrated impressive long-term outcomes, particularly in carcinoma in situ patients where complete responders achieved 92% response rates at three years compared to two-thirds with BCG alone. #FullVideo on UroToday > bit.ly/4mRZQJT

English
4
6
20
3.4K
Bernie Bochner, MD retweetledi
Yash Khandwala, MD
Yash Khandwala, MD@YashKhandwalaMD·
New data on outcomes after consolidative nephrectomy published in EU Oncology! Our findings suggest that a major pathologic response after ICI therapy for metastatic RCC is associated with long PFS and OS. Full study here: sciencedirect.com/science/articl…
Yash Khandwala, MD tweet media
English
1
10
28
2.6K
Bernie Bochner, MD retweetledi
David H Aggen, MD PhD
David H Aggen, MD PhD@Dr_Aggen·
🚀 Exciting advances in NMIBC at @MSKCancerCenter led by @UrologyMSK 🚨 Pragmatic trial for BCG-refractory NMIBC Led by Eugene Pietzak (@eugene_pietzak) — Trial #25-069 / NCT06929286 mskcc.org/cancer-care/cl… clinicaltrials.gov/study/NCT06929… 🚨 CD40 Agonist Trial for BCG-unresponsive NMIBC Led by Bernie Bochner (@bbmdmsk) A shining example of bench to bedside medicine co-led by @juanosoriomd Trial #21-314 / NCT05126472. mskcc.org/cancer-care/cl… clinicaltrials.gov/study/NCT05126… Proud work from @urologymsk @MSKCancerCenter @BladderCancerUS
English
2
7
21
2K
Bernie Bochner, MD retweetledi
David H Aggen, MD PhD
David H Aggen, MD PhD@Dr_Aggen·
🚨 New trial options at @MSKCC for advanced bladder cancer after EV+P. • HER2-targeted ADC: clinicaltrials.gov/study/NCT05322… (Disitamab Vedotin) • TROP2-ADC: clinicaltrials.gov/study/NCT05854… (Datopotomab Deruxtecan) • Nectin-4-ADC: clinicaltrials.gov/study/NCT06465… (“Nectin-4 targeted ADCs”) • Pan-tumor CDH6-ADC: clinicaltrials.gov/study/NCT06660… (Raludotatug Deruxtecan) @MSK_Urology @MSK_DeptOfMed @MSKCC #BladderCancer #ClinicalTrials
English
5
16
54
5.7K
Bernie Bochner, MD retweetledi
Nick Pickersgill, MD
Nick Pickersgill, MD@NickPickersgill·
Our new study finds biparametric MRI offers diagnostic performance similar to multiparametric MRI for suspected prostate cancer, aligning with the recent PRIME trial results. Pros: shorter scan time, omitting contrast, lower cost. link.springer.com/article/10.100…
Nick Pickersgill, MD tweet media
English
0
1
20
2K
Columbia Urology
Columbia Urology@ColumbiaUrology·
We’re proud to share that Dr. Ojas Shah @shah_ojas is the new Chair of Columbia Urology! After serving as interim chair during a critical year, he’s led with steadiness & vision — we’re confident in his continued leadership ahead. 🌅 @ColumbiaMed @Endo_Society @AmerUrological
Columbia Urology tweet media
English
27
11
132
17.8K
rachel bochner
rachel bochner@rachel_bochner·
your Manhattan in less than a week
English
3
2
28
702
Bernie Bochner, MD retweetledi
Manan Shah
Manan Shah@MananShahmd·
Remember when they tried to ‘ban’ surgeons caps?! The AORN decided we all needed to wear lunch lady hats. But then studies showed it made no difference. Such a random and wild example nonesense in medicine where doctors get told what to do.
Manan Shah tweet media
English
37
38
300
111.6K
Bernie Bochner, MD
Bernie Bochner, MD@bbmdmsk·
Incredible work by Jeff Ravitch @juanosoriomd and team Our ongoing research in bladder cancer using this CD40 platform continues to show exciting results Great collaboration between @MSKCancerCenter @RockefellerUniv @DrRosenbergMSK @eugene_pietzak @UrologyMSK
Juan C Osorio MD@juanosoriomd

Thrilled to share our new publication on the first-in-human phase 1 trial of intratumoral Fc-engineered CD40 agonistic antibody 2141-V11 in metastatic cancer. Over 10 years of preclinical work led to this moment, made possible by an amazing team! 🧵 🪡 cell.com/cancer-cell/fu…

English
2
3
28
1.6K

Keşfet

@Olympus_Corp @DrJohnSfakianos @JoshMeeks @olympusamerica @UrologyMSK @eugene_pietzak @MaxKates @predicine